Virax Biolabs Group Ltd (VRAX)

Currency in USD
9.2714
+6.0914(+191.55%)
Real-time Data·
Unusual trading volume
VRAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.400013.1700
52 wk Range
2.500028.5000
Key Statistics
Prev. Close
3.18
Open
11
Day's Range
8.4-13.17
52 wk Range
2.5-28.5
Volume
59.1M
Average Volume (3m)
1.04M
1-Year Change
-59.398%
Book Value / Share
25.52
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VRAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
25.0000
Upside
+169.65%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Virax Biolabs Group Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 25.0000
(+169.65% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy1.00-89.14%3.00MaintainJan 12, 2026

Earnings

Latest Release
Jul 06, 2026
EPS / Forecast
-4.45 / --
Revenue / Forecast
10.82K / --
EPS Revisions
Last 90 days

VRAX Income Statement

Compare VRAX to Peers and Sector

Metrics to compare
VRAX
Peers
Sector
Relationship
P/E Ratio
−0.5x−5.8x−0.4x
PEG Ratio
−0.010.360.00
Price/Book
0.3x3.3x2.6x
Price / LTM Sales
204.0x2.4x3.0x
Upside (Analyst Target)
-5.1%51.9%
Fair Value Upside
Unlock2.6%9.4%Unlock

Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.000.00%3.18
Other Institutional Investors
81.65K10.25%259.65K
Public Companies & Retail Investors
715.29K89.75%2.27M
Total
796.94K100.00%2.53M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Armistice Capital LLC5.02%40,010127
Armistice Capital Master Fund Ltd.5.02%40,010127

People Also Watch

1.3832
HUBC
-1.20%
1.3901
QUCY
+2.97%
9.1100
ASTC
0.00%
1.560
QTEX
-3.11%
3.75
TDIC
-5.78%

FAQ

What Is the Virax Biolabs (VRAX) Stock Price Today?

The Virax Biolabs stock price today is 9.2714 USD.

What Stock Exchange Does Virax Biolabs Trade On?

Virax Biolabs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Virax Biolabs?

The stock symbol for Virax Biolabs is "VRAX."

What Is the Virax Biolabs Market Cap?

As of today, Virax Biolabs market cap is 2.5300M USD.

What Is Virax Biolabs's Earnings Per Share (TTM)?

The Virax Biolabs EPS (TTM) is -12.6400.

From a Technical Analysis Perspective, Is VRAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Virax Biolabs Stock Split?

Virax Biolabs has split 2 times.

How Many Employees Does Virax Biolabs Have?

Virax Biolabs has 26 employees.

What is the current trading status of Virax Biolabs (VRAX)?

As of Jul 09, 2026, Virax Biolabs (VRAX) is trading at a price of 9.2714 USD, with a previous close of 3.1800 USD. The stock has fluctuated within a day range of 8.4000 USD to 13.1700 USD, while its 52-week range spans from 2.5000 USD to 28.5000 USD.

What Is Virax Biolabs (VRAX) Price Target According to Analysts?

The average 12-month price target for Virax Biolabs is 25.0000 USD, with a high estimate of 25 USD and a low estimate of 25 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +169.65% Upside potential.

What Is the VRAX Premarket Price?

VRAX's last pre-market stock price is 10.8000 USD. The pre-market share volume is 32,780,000.0000, and the stock has decreased by 7.6200, or 239.6200%.

What Is the VRAX After Hours Price?

VRAX's last after hours stock price is 3.0100 USD, the stock has decreased by -0.1700, or -5.3500%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.